Skip to main content
Clinical Trials/JPRN-UMIN000040163
JPRN-UMIN000040163
Completed
未知

Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA) - Study for the pathogenesis of eosinophilic polyangiitis granulomatosis (EGPA)

ational Hospital Organization Sagamihara National Hospital0 sites100 target enrollmentApril 20, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
Eosinophilic granulomatosis with polyangiitis
Sponsor
ational Hospital Organization Sagamihara National Hospital
Enrollment
100
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

In active EGPA, 33 proteins, mainly related to eosinophils, type 2 inflammation, and cell adhesion factors, were elevated compared to asthma. In contrast, 12 proteins were decreased with steroid treatment. Fifty-nine proteins, including functional proteins involved in cell proliferation, angiogenesis, and type 3 inflammation as well as eosinophilic inflammation, were altered by the additional administration of mepolizumab. MicroRNA coverage analysis showed 8 significantly different between EGPA and asthma.

Registry
who.int
Start Date
April 20, 2020
End Date
November 30, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
ational Hospital Organization Sagamihara National Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Individuals who are judged to be ineligible by the study representative or the treating physician

Outcomes

Primary Outcomes

Not specified

Similar Trials